Danaher Co. (NYSE:DHR) Shares Purchased by Triangle Securities Wealth Management

Triangle Securities Wealth Management increased its position in shares of Danaher Co. (NYSE:DHR - Free Report) by 50.2% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,628 shares of the conglomerate's stock after purchasing an additional 1,882 shares during the quarter. Triangle Securities Wealth Management's holdings in Danaher were worth $1,154,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of DHR. Spinnaker Trust boosted its stake in shares of Danaher by 1.2% in the fourth quarter. Spinnaker Trust now owns 4,304 shares of the conglomerate's stock worth $988,000 after buying an additional 50 shares during the last quarter. Fortis Capital Advisors LLC boosted its position in Danaher by 1.3% in the 4th quarter. Fortis Capital Advisors LLC now owns 3,983 shares of the conglomerate's stock worth $914,000 after purchasing an additional 50 shares in the last quarter. Fayez Sarofim & Co grew its stake in shares of Danaher by 0.6% during the 4th quarter. Fayez Sarofim & Co now owns 8,287 shares of the conglomerate's stock worth $1,902,000 after purchasing an additional 50 shares during the period. Coastal Bridge Advisors LLC increased its holdings in shares of Danaher by 4.8% during the 4th quarter. Coastal Bridge Advisors LLC now owns 1,099 shares of the conglomerate's stock valued at $252,000 after purchasing an additional 50 shares in the last quarter. Finally, Perennial Investment Advisors LLC lifted its stake in shares of Danaher by 2.2% in the 4th quarter. Perennial Investment Advisors LLC now owns 2,343 shares of the conglomerate's stock valued at $538,000 after purchasing an additional 51 shares during the period. Hedge funds and other institutional investors own 79.05% of the company's stock.

Insider Activity

In other Danaher news, Chairman Steven M. Rales sold 1,250,000 shares of Danaher stock in a transaction on Monday, May 12th. The stock was sold at an average price of $196.74, for a total value of $245,925,000.00. Following the sale, the chairman now owns 3,105,808 shares in the company, valued at $611,036,665.92. The trade was a 28.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Christopher Paul Riley sold 15,805 shares of the stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total value of $3,129,390.00. Following the transaction, the executive vice president now owns 15,179 shares of the company's stock, valued at approximately $3,005,442. This represents a 51.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 11.10% of the company's stock.

Danaher Price Performance

DHR stock traded down $1.16 during mid-day trading on Thursday, reaching $191.92. The company's stock had a trading volume of 3,096,463 shares, compared to its average volume of 3,476,559. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. The company's 50 day moving average is $191.68 and its two-hundred day moving average is $212.83. Danaher Co. has a fifty-two week low of $171.00 and a fifty-two week high of $281.70. The stock has a market cap of $137.35 billion, a PE ratio of 36.35, a P/E/G ratio of 2.66 and a beta of 0.80.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 EPS for the quarter, beating the consensus estimate of $1.62 by $0.26. The firm had revenue of $5.74 billion during the quarter, compared to analysts' expectations of $5.58 billion. Danaher had a return on equity of 10.82% and a net margin of 16.33%. Equities research analysts expect that Danaher Co. will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be issued a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.67%. Danaher's dividend payout ratio is presently 24.85%.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Robert W. Baird dropped their price target on shares of Danaher from $231.00 to $225.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 23rd. HSBC dropped their target price on Danaher from $270.00 to $240.00 in a research report on Friday, April 25th. Royal Bank of Canada restated an "outperform" rating and issued a $250.00 price target on shares of Danaher in a research note on Wednesday, April 23rd. Wall Street Zen upgraded Danaher from a "hold" rating to a "buy" rating in a research report on Sunday. Finally, The Goldman Sachs Group reduced their target price on Danaher from $260.00 to $240.00 and set a "neutral" rating for the company in a research note on Wednesday, April 23rd. Four research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company's stock. Based on data from MarketBeat, Danaher currently has an average rating of "Moderate Buy" and an average target price of $263.24.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.